Canterbury DHB



This refers to the infusion of blood or recombinant products in anticipation of or in order to prevent bleeding. This contrasts with on-demand therapy given at the first sign of a bleed.

Prophylaxis may be:

Who should receive prophylaxis?

Primary prophylaxis is standard treatment for infants with severe haemophilia (<1% factor) who declare themselves at high risk for the development of haemophiliac arthropathy.

When should treatment start?

In general, treatment is commenced within the first 12-24 months of life. It is normally commenced following the first significant spontaneous bleed (joint or soft tissue). A Port-a-Cath device may be needed to facilitate vascular access.

Short-term prophylaxis may be required for a patient with recurrent bleeding into a target joint.

In This Section

Haemophilia A

Haemophilia B

About this Canterbury DHB document (5236):

Document Owner:

Mark Smith (see Who's Who)

Issue Date:

August 2016

Next Review:

August 2019


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5236